Massachusetts General Hospital
The goal of this prospective, non-randomized pilot study is to learn whether predictions from a previously validated 12-lead ECG-based artificial intelligence (AI) algorithm (ECG-AI) identify people more likely to have undiagnosed atrial fibrillation (AF). The main questions it aims to answer are: Do people predicted to have high risk of AF using ECG-AI have a higher rate of new AF diagnosis using 1L ECG screening compared with people predicted to have a low risk? Do AI-based AF risk estimates from the 12-lead ECG correlate with AF risk estimates from the 1L ECG? Do people find 1L ECG screening for AF acceptable and useful? Participants will: Undergo screening with 1L ECG mailed to their home Complete a survey assessing attitudes toward 1L ECG screening Complete a 14-day patch monitor on 1 or 2 occasions depending on 1L ECG results
This is a prospective, non-randomized pilot study designed to assess whether our 12-lead ECG algorithm can identify individuals with AF detectable using 1L ECG. We will also assess whether AF risk estimates from the 1L ECG correlate with those using the 12-lead ECG. We also plan to assess participant attitudes toward the use of 1L ECGs for AF risk estimation. Using our AF risk algorithm on existing 12-lead ECGs, will categorize prospective participants into low AF risk (\<1% 1-year AF risk) versus high AF risk (\>10% 1-year AF risk). We will mail 1L ECG devices to participants and ask them to…
Inclusion Criteria: * Men and women aged 50-90 who are new or established patients in an MGH primary care or ambulatory cardiology practice * Willing to provide consent to participate in the study to access data from electronic health records (EHR) * At least 1 12-lead ECG obtained within 5 years prior to study start date for AF risk estimation * Have access to a smart phone or tablet to use with the AliveCor KardiaMobile 1L ECG device Exclusion Criteria: * History of atrial fibrillation or atrial flutter as documented in the patient's current electronic health record medical problem list o…
Individuals will undergo 1L ECG screening using the AliveCor KardiaMobile 1L ECG device
Individuals who are found to have evidence of AF on 1L ECG will undergo assessment with 14-day patch monitor at the time of initial screen. Otherwise all study participants will undergo 14-day patch monitor at the 1-year timepoint.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.